FindTrial
Sign In

The efficacy and safety of etoposide in mobilization of autologous hematopoietic stem cell transplantation in multiple myeloma: a prospective, multicenter, open-label and observational study

The efficacy and safety of etoposide in mobilization of autologous hematopoietic stem cell transplantation in multiple myeloma: a prospective, multicenter, open-label and observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056948
Enrollment
Unknown
Registered
2022-02-24
Start date
2022-02-24
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Case series:Nil

Sponsors

The First Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.18 years or above; 2.Patients with multiple myeloma requiring autologous hematopoietic stem cell transplantation;

Exclusion criteria

Exclusion criteria: 1. Do not sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
CD34 + cell count;time required for single collection;collection times;—

Secondary

MeasureTime frame
the safety of etoposide mobilization scheme (including adverse drug reactions and tolerance).;the excellent and good rate of etoposide mobilization scheme.;the hematopoietic reconstruction time after transplantation of etoposide mobilization scheme;—

Countries

China

Contacts

Public ContactFengyan JIin

The First Hospital of Jilin University

fengyanjin@jlu.edu.cn+86 13844989638

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026